FDA Approves Dupilumab for Allergic Fungal Rhinosinusitis: First Indication for AFRS

Executive Brief

News Report

The News: Dupilumab has been approved for the treatment of allergic fungal rhinosinusitis.
Clinical Win: This approval provides a new option for managing a challenging condition with significant complications.
Target Specialty: Otolaryngology

Key Data at a Glance

Approval Date: February 24, 2026
Study Duration: 52 weeks
Enrollment: 300 patients

The FDA has approved dupilumab (Dupixent) for the treatment of allergic fungal rhinosinusitis (AFRS) in adult and pediatric patients aged 6 years and older with a history of sino-nasal surgery. This approval marks the first indication for dupilumab in treating this uncommon but serious condition, which can lead to severe complications if left untreated. The announcement was made on February 24, 2026.

Clinical Context

Allergic fungal rhinosinusitis (AFRS) is a subtype of chronic rhinosinusitis characterized by an allergic response to fungal elements in the sinuses, leading to significant inflammation and mucus production. This condition affects approximately 8% of individuals with chronic sinusitis and nasal polyps, particularly in humid climates where fungi proliferate. Symptoms can include nasal congestion, facial pain, and loss of smell, and if untreated, AFRS can result in extensive bone erosion and serious complications, including vision problems and neurological damage. Current treatments often involve systemic corticosteroids and surgical interventions, but these approaches can be inadequate for many patients. Dupilumab, a monoclonal antibody that inhibits interleukin-4 and interleukin-13 signaling, offers a new therapeutic option aimed at controlling the underlying inflammatory processes in AFRS.

Key Findings

The FDA approval of dupilumab for AFRS is based on a 52-week study demonstrating significant improvements in sinus opacification compared to placebo, as measured by the Lund-Mackay score [1].

The trial enrolled 300 adult and pediatric patients aged 6 years and older with a history of sino-nasal surgery and confirmed AFRS [1].

Dupilumab treatment resulted in a 50% reduction in the need for systemic corticosteroids and a 40% decrease in the necessity for additional sinus surgeries compared to placebo over the study period [1].

The primary endpoint was the change in Lund-Mackay score from baseline to week 52, showing substantial improvements in sinus health and patient-reported outcomes, such as nasal congestion and sense of smell [1].

What This Means for Clinical Practice

The approval of dupilumab for AFRS provides clinicians with a novel treatment option for patients who have not responded adequately to traditional therapies. This biologic therapy may reduce the frequency of surgical interventions and systemic corticosteroid use, addressing a significant unmet need in managing AFRS. Clinicians should consider incorporating dupilumab into treatment plans for eligible patients, particularly those with recurrent symptoms or severe disease manifestations. As with any new treatment, ongoing monitoring for efficacy and safety will be essential to optimize patient outcomes and ensure the best care practices are followed.

Clinical Perspective

Workflow: The introduction of dupilumab into clinical practice for AFRS may streamline treatment protocols, reducing reliance on surgery.

Economics: By potentially decreasing the need for surgical interventions and systemic corticosteroids, dupilumab could lower overall healthcare costs associated with managing AFRS.

Patient Outcomes: With improved management of AFRS symptoms, patients may experience enhanced quality of life and reduced complications.

Editorial Team, Otolaryngology

References

FDA — FDA approves drug for adult and pediatric patients aged 6 and older with allergic fungal rhinosinusitis